1532 - Expansion of MBS item 73325 to include additional populations and mutations beyond those currently specified (for the characterisation of JAK2 or MPL genes)

Page last updated: 08 March 2019

Application Detail

Status

Open

Description of Medical Service

Molecular testing for the diagnosis of polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) can establish the presence or absence of specific mutations known to occur in patients with these disorders. MBS item 73325 currently provides for Janus kinase (JAK2) and myeloproliferative leukaemia (MPL) gene testing in patients with PV or ET. The proposed medical service being requested is the expansion of MBS item 73325 to allow testing for calreticulin (CALR) mutations in patients with PV or ET, and testing for JAK2, MPL and CALR genes in patients with primary myelofibrosis (PMF).

Description of Medical Condition

Myeloproliferative neoplasms (MPNs) are a group of disorders in which bone marrow stem cells grow and reproduce abnormally. PV, ET and PMF are MPN's.


Reason for Application

-

Medical Service Type

Investigative

Previous Application Number

1125

Associated Documentation

Application Form

-

Consultation Survey

-

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

-

ESC

-

MSAC

-